May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Nina Chavez: OCM Has Made Community Oncologists Better Business People
Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM
Dr James Hamrick Discusses Bringing Value to Patients Through Engagement
Lessons From the Field: How Practices Are Succeeding Under OCM
Mike Fazio: Practices Are Happier With PP4 Results in the OCM